Featured
Pharma spend on HCPs shrinks
Companies lowered the amount they spent on HCPs each month in the first half of 2026, with just two pharmas getting into seven figures
Jobs & Workplace
Companies line up talent for 2027
There's been a wave of movement across Australian pharma with promotions, new hires, departures and even a retirement as a new year looms
Regulation & Legal
Novartis gene therapy hit by cancer fears
A theoretical side-effect of the gene therapy has appeared in practice, alarming patient networks around the world
Jobs & Workplace
Pharma urged to grow Aussie workforce
New report on the Australian clinical trials workforce reveals the same people are either being reshuffled or lost, while others struggle to crack the market
Industry & Companies
Scam headhunters targeting Aussie pharma execs
Scammers impersonating legitimate Big Pharma in-house recruiters are targeting Australian industry professionals with lucrative high-income roles as part of a money-making racket
Leadership & People
Ex-CSL exec steps into CEO role
After eight-plus years with the Aussie giant, this industry leader has taken a CEO role at a biotech with big ambitions to transform precision medicine
Pipeline & Intellectual Property
Supply setback extends shortage into 2027
A national shortage of this treatment is expected to continue into 2027 after the pharma confirmed an order, expected this month, is now “unlikely”
Sales, Marketing & Public Relations
New access model reshaping pharma
Direct-to-patient programs are considered "mission critical" according to a third of pharma professionals who believe it will transform access
Patients
Riders pedal past fundraising target
Aussie BMS staffers have raised double their original goal for Rare Cancers Australia through an 18,000 kilometre, 15-day cycling event in Japan
Latest
Matt Zeller launches new Australian pharma
Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder
Industry & Companies
Pharma sold at undisclosed price
An international private equity firm has reached an agreement to acquire this pharma, with plans to support its global growth ambitions
Featured
Was this Aussie pharma's Best Kept Secret?
A bombshell announcement from two industry high-flyers was kept completely under wraps despite multiple big-name organisations getting on board with the new pharma venture. And now, they've detailed a potentially market-disrupting business model for medicines access
Government & Policy
Boosting PBS spending a political no-brainer
New research commissioned by Pfizer Australia exposes near-universal public support for expanding the PBS among Coalition, Labor, Greens and One Nation voters
Industry & Companies
Roche unveils new tech for high-throughput genomics
The Swiss pharma is gathering experts to push its entrant into the booming next-generation sequencing market
Regulatory & Reimbursement
New drugs flood the ARTG
Last week saw a string of medicines registered on the ARTG, including two heart drugs, a new contraceptive option, and Novo’s hyped obesity pill
Featured
Pfizer names permanent ANZ leader
He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape
Jobs
Leadership & People
Country boss adds new leadership hat
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
Sales, Marketing & Public Relations
What doctors really want Reps to talk about
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
Regulatory & Reimbursement
Drugs dropped from PBAC meeting
Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026
Industry & Companies
Pharma sells off Aussie business
This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M
Featured
11 drugs join TGA review list
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Pipeline & Intellectual Property
Pharma signs its biggest ever milestones deal
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs
Patients
Omico names genomic profiling partners
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
Regulatory & Reimbursement
What drugs are on MS patients' Wish List?
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
Industry & Companies
One webpage, 11 Code Breaches
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee
Pipeline & Intellectual Property
Drug fails four months after $2.2B upfront buy
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
Government & Policy
Blue wave to break against MFN
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
Pipeline & Intellectual Property
Can pharma sustain the blockbuster boom?
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
- Jobs & Workplace Aussies tapped for regional roles
- Regulatory & Reimbursement Pharmac says no to weight loss funding
- Regulatory & Reimbursement Aussie race to market kicks off for obesity pills
- Industry & Companies Who's opening its doors in the US?
- Industry & Companies AZ shuffles jobs to prep huge pipeline
- Awards Meet the Best Drugs of 2026
- Regulatory & Reimbursement Aussie study applauds new-gen Novartis drug
- Leadership & People Ex-Novartis GM snapped up for global role
- Pipeline & Intellectual Property Qld radiopharma defends manufacturing process
- Pipeline & Intellectual Property Aussies find new combo to tackle deadly cancer